"Stamford Company Launches Disease-Screening Product For Newborns" - Alfred Branch
A Mount Sinai Health System venture, Sema4, a health information company providing advanced genomic testing, announced the launch of Sema4 Natalis, a supplemental newborn screening test designed to detect 193 childhood-onset diseases or disorders so parents can gain insight into their baby's health. This simple genetic test can be performed at home with a gentle cheek swab. "Until now, families have been likely to be caught off-guard by these early-onset diseases, and prognosis is often poor by the time symptoms have manifested. Thanks to breakthroughs in science and medicine, we can now identify babies at risk for these broader set of diseases and deliver interventions - sometimes as simple as vitamin supplements - in time to make a real difference," said Eric Schadt, PhD, dean of precision medicine, professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai, and founder and CEO of Sema4. "We believe Sema4 Natalis will give parents the advantage of early insight in support of the care of their children."
- Eric Schadt, PhD, Dean, Precision Medicine, Professor, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, Founder and CEO, Sema4
Additional coverage
Stamford Patch
New Canaan Patch
Erie News
Xconomy
TMC News
MIT Technology Review
Hartford Business
The Week Magazine
Financial Buzz
Stamford Advocate
Digital Journal
Sanofi, Sema4, Mount Sinai Collaborate on Largest Asthma Study of Its Kind
Dec 04, 2018 View All Press ReleasesSema4 Launches Supplemental Newborn Screening Test for 190+ Childhood-Onset Diseases
Feb 07, 2018 View All Press Releases